Vitekta is a drug owned by Gilead Sciences Inc. It is protected by 6 US drug patents filed from 2014 to 2021 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 26, 2027. Details of Vitekta's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | |||
| US7176220 | 4-oxoquinoline compound and use thereof as pharmaceutical agent |
Aug, 2026
(2 years from now) | Active |
| US7635704 | Stable crystal of 4-oxoquinoline compound |
Oct, 2026
(2 years from now) | Active |
| US8981103 | Stable crystal of 4-oxoquinoline compound |
Oct, 2026
(2 years from now) | Active |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
|
US7176220 (Pediatric) | 4-oxoquinoline compound and use thereof as pharmaceutical agent |
Feb, 2027
(2 years from now) | Active |
|
US8981103 (Pediatric) | Stable crystal of 4-oxoquinoline compound |
Apr, 2027
(2 years from now) | Active |
|
US7635704 (Pediatric) | Stable crystal of 4-oxoquinoline compound |
Apr, 2027
(2 years from now) | Active |
FDA has granted several exclusivities to Vitekta. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Vitekta, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Vitekta.
Exclusivity Information
Vitekta holds 2 exclusivities. All of its exclusivities have expired in 2017. Details of Vitekta's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 27, 2017 |
| New Product(NP) | Sep 24, 2017 |
US patents provide insights into the exclusivity only within the United States, but Vitekta is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Vitekta's family patents as well as insights into ongoing legal events on those patents.
Vitekta's family patents
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳
Generic Launch
Generic Release Date:
Vitekta's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Apr 26, 2027 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Vitekta Generics:
There are no approved generic versions for Vitekta as of now.
About Vitekta
Vitekta is a drug owned by Gilead Sciences Inc. It is used for managing HIV infection. Vitekta uses Elvitegravir as an active ingredient. Vitekta was launched by Gilead Sciences Inc in 2014.
Market Authorisation Date:
Vitekta was approved by FDA for market use on 24 September, 2014.
NCE-1 date:
NCE-1 date is also known as the four year date as it is four years after the original drug approval. Since the approval date for Vitekta is 24 September, 2014, its NCE-1 date is estimated to be 27 August, 2016
Active Ingredient:
Vitekta uses Elvitegravir as the active ingredient. Check out other Drugs and Companies using Elvitegravir ingredient
Treatment:
Vitekta is used for managing HIV infection.
Dosage:
Vitekta is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 85MG | TABLET | Discontinued | ORAL |
| 150MG | TABLET | Discontinued | ORAL |